This Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity and pharmacodynamic effects of SL-172154 when administered as an intratumoral injection (ITI) and identify the dose and schedule i.e., recommended Phase 2 dose (RP2D) for future development. 

The study design consists of four sequential dose-escalation cohorts and an optional pharmacodynamic cohort to obtain additional pharmacodynamic data at one or more dose levels that have completed evaluation for safety without exceeding the maximum tolerated dose (MTD). Patients will be injected with SL-172154 on days 1, 8 and 15 during cycle 1, and then day 1 of each subsequent 21 day cycle. 

(SL03-OHD-102, IRB 2020-0583)

IRB 2020-0165
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
IRB 2020-1070
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included

It takes only seconds to get the new app. On your phone, simply go to Add the app to your home screen for quick and easy use.  Please delete all other prior versions of the app. 

If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, or Ginger Conway @859-992-5339,



Dylan and Ginger

A new combination for cancer treatment

A UC study, led by Christina Wicker, a postdoctoral fellow in the lab of Vinita Takiar, MD, PhD, found an approved drug could make radiation therapy more effective for head and neck cancer. Using animal models, researchers found that the drug alone reduced the growth of head and neck cancer cells up to 90%, and it also increased the efficacy of radiation in animals with head and neck tumors by 40% 
Click Here to Visit the UC Newsroom
Division of Hematology Oncology Grand Rounds Schedule
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Questions?  Please call us at 513-584-7698, or email us!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA